Sandoz’s Enbrel Biosimilar Filing May Spur New Litigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Etanercept biosimilar could face more complications on both patent and review front than Zarxio experienced.
You may also be interested in...
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.